Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 227
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
Three Brain Injuries, One Iboga Protocol, and What It Tells Us
The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.
A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...
MindMed CMO to Chair Digital Biomarkers Summit
Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial...
Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson...
More Evidence of the Chemical Compound Variability in Magic Mushrooms
PTSF82 – Wonderland Miami, with Patrick Moher of Microdose
Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy...
Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in...
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Load more